((自动化翻译由路透提供，请见免责声明 ))
12月9日 - ** 细胞疗法开发商Arcellx 的股价盘前上涨8%至91.35美元
** 该公司称其细胞疗法anito-cel在一项测试多发性骨髓瘤（一种血癌）患者的中期试验中显示出97%的总体反应率 (link)
** 总体反应率是指对疗法有部分或完全反应的患者比例。
** 与吉利德公司 合作开发的anito-cel如果获得批准，将与强生公司 的细胞疗法Carvykti竞争。
** 券商 TD Cowen 称，anito-cel 的疗效至少与 Carvykti 相当，但安全性更高
** ACLX 的疗法没有显示出对神经系统的延迟损伤，但在试验期间有 3 人因不良事件死亡
** 截至上次收盘，股价累计上涨 52.3
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.